Welcome to the AxBlog. sign up for updates Bithia Anderson 6/29/21 Bithia Anderson 6/29/21 Gene Therapy and Coverage Considerations Read More Bithia Anderson 6/27/21 Bithia Anderson 6/27/21 Key Drug Trends in 2020 Read More Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Are PBMs Covering Biosimilars?(Part 5 of 5) Read More Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 April 2021 New Drug Approvals Read More Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Understanding Physician and Patient Perception of Biosimilars Read More Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Biologics legislation heads to Biden's desk for signature. Read More Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Price transparency ads have no impact on lowering prices. Read More Bithia Anderson 5/30/21 Bithia Anderson 5/30/21 Not so fast! Biosimilars face anemic adoption. What Plan Sponsors Should Know (Part 4 of 5). Read More Bithia Anderson 4/21/21 Bithia Anderson 4/21/21 State legislation on biosimilar substitution (Part 2 of 5) Read More Bithia Anderson 4/21/21 Bithia Anderson 4/21/21 Management & Barriers to Uptake of Biosimilars under Pharmacy vs. Medical Benefit (Part 3 of 5) Read More Bithia Anderson 4/21/21 Bithia Anderson 4/21/21 March 2021 New Drug Approvals Read More Bithia Anderson 4/21/21 Bithia Anderson 4/21/21 Review of NBER Working Paper Series. Biosimilar Competition: Early Learning Read More Del Doherty 3/18/21 Del Doherty 3/18/21 February 2021 New Drug Approvals Read More Bithia Anderson 3/18/21 Bithia Anderson 3/18/21 Frozen Formularies Can Raise Drug Costs Read More Bithia Anderson 3/18/21 Bithia Anderson 3/18/21 Biosimilars to Remicade Found to Have Comparable Clinical Response to Reference Product Read More Bithia Anderson 3/17/21 Bithia Anderson 3/17/21 Biosimilars wreak an all too familiar headache. What plan sponsors should know (Part 1 of 5). Read More Del Doherty 2/13/21 Del Doherty 2/13/21 January 2021 New Drug Approvals Read More Bithia Anderson 2/12/21 Bithia Anderson 2/12/21 Trends in Specialty Drug Approvals & Management Read More Bithia Anderson 2/2/21 Bithia Anderson 2/2/21 Rebate Rule Not in Effect until 2023 Read More Bithia Anderson 2/2/21 Bithia Anderson 2/2/21 Limited Distribution Networks (LDNs) delay patient access to crucial medications. Read More Newer Posts Start your journey with Axum
Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Are PBMs Covering Biosimilars?(Part 5 of 5) Read More
Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Understanding Physician and Patient Perception of Biosimilars Read More
Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Biologics legislation heads to Biden's desk for signature. Read More
Bithia Anderson 5/31/21 Bithia Anderson 5/31/21 Price transparency ads have no impact on lowering prices. Read More
Bithia Anderson 5/30/21 Bithia Anderson 5/30/21 Not so fast! Biosimilars face anemic adoption. What Plan Sponsors Should Know (Part 4 of 5). Read More
Bithia Anderson 4/21/21 Bithia Anderson 4/21/21 State legislation on biosimilar substitution (Part 2 of 5) Read More
Bithia Anderson 4/21/21 Bithia Anderson 4/21/21 Management & Barriers to Uptake of Biosimilars under Pharmacy vs. Medical Benefit (Part 3 of 5) Read More
Bithia Anderson 4/21/21 Bithia Anderson 4/21/21 Review of NBER Working Paper Series. Biosimilar Competition: Early Learning Read More
Bithia Anderson 3/18/21 Bithia Anderson 3/18/21 Biosimilars to Remicade Found to Have Comparable Clinical Response to Reference Product Read More
Bithia Anderson 3/17/21 Bithia Anderson 3/17/21 Biosimilars wreak an all too familiar headache. What plan sponsors should know (Part 1 of 5). Read More
Bithia Anderson 2/12/21 Bithia Anderson 2/12/21 Trends in Specialty Drug Approvals & Management Read More
Bithia Anderson 2/2/21 Bithia Anderson 2/2/21 Limited Distribution Networks (LDNs) delay patient access to crucial medications. Read More
